205059-23-0

Basic information

• Product Name: 4-[1-(phenylmethyl)-4-piperidinyl]-1-(1,1-dimethylethoxycarbonyl)-piperazine
• Synonyms: 4-[1-(phenylmethyl)-4-piperidinyl]-1-(1,1-dimethylethoxycarbonyl)-piperazine
• CAS NO: 205059-23-0
• Molecular Weight: 359.512
• Mol File: 205059-23-0.mol

Chemical Properties

• CAS DataBase Reference: 4-[1-(phenylmethyl)-4-piperidinyl]-1-(1,1-dimethylethoxycarbonyl)-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[1-(phenylmethyl)-4-piperidinyl]-1-(1,1-dimethylethoxycarbonyl)-piperazine(205059-23-0)
• EPA Substance Registry System: 4-[1-(phenylmethyl)-4-piperidinyl]-1-(1,1-dimethylethoxycarbonyl)-piperazine(205059-23-0)

Safety Data

• Hazardous Substances Data: 205059-23-0(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 205059-24-1 tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate 

Relevant articles and documents

NEW COMPOUNDS

The present invention encompassescompounds of general formula (1) wherein R1 to R4 , X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised byexcessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof

The present invention relates to carboxylic acids and esters of general formula wherein Ar, R, R1, X1, X3, X4, Y and Y1 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof, as well as the use thereof for the production and purification of antibodies and as labelled compounds in RIA and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Modified amino acids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.